CymaBay Therapeutics (CBAY) Coverage Initiated at Evercore ISI


Cantor Fitzgerald maintained Cymabay Therapeutics, Inc. The firm has "Buy" rating by Piper Jaffray given on Tuesday, July 25. The company was maintained on Wednesday, September 9 by Needham. Investors mark this stock "active" as it exchanged hands with 1,308,856 shares contrast to its average daily volume of 719.11K shares. The firm earned "Buy" rating on Tuesday, January 2 by Brean Capital. The stock has "Buy" rating by Robert W. Baird on Friday, November 17. After keeping Technical check on movement of stock price comparison to its moving averages like 20, 50 and 200 SMA, we detected following trends of CBAY. As per Thursday, July 21, the company rating was initiated by Lake Street. Northland Capital maintained the shares of FLXN in report on Wednesday, October 4 with "Buy" rating. On Wednesday, June 1 the stock rating was downgraded by H.C. Wainwright to "Neutral". (NASDAQ:CBAY) can provide us with excellent insight into how the company's stock is performing. The rating was upgraded by H.C. Wainwright to "Buy" on Monday, January 30. The rating was maintained by Brean Capital with "Buy" on Friday, December 1. The firm has "Buy" rating given on Tuesday, September 8 by H.C. Wainwright. Heritage Invsts Mngmt holds 148,204 shares or 0.37% of its portfolio. The stock increased 0.70% or $0.17 during the last trading session, reaching $24.58. About 6.05 million shares traded or 581.70% up from the average. Comcast Corporation (NASDAQ:CMCSA) has risen 28.96% since February 16, 2017 and is uptrending. It has underperformed by 24.43% the S&P500.

The stock decreased 5.66% or $1.39 during the last trading session, reaching $23.19. About 1.85M shares traded or 142.22% up from the average. Flexion Therapeutics, Inc. (NASDAQ:FLXN) has risen 82.02% since February 17, 2017 and is uptrending. It has outperformed by 65.32% the S&P500.

Investors sentiment decreased to 1.22 in 2017 Q3. Its up 0.02, from 1.01 in 2017Q2. 22 funds opened positions while 28 raised stakes. (NASDAQ:ENTG). California State Teachers Retirement invested in 227,580 shares.

Israel's Netanyahu could act against Iran's "empire"
Earlier this month, Tel Aviv claimed that it had responded to the infiltration of an Iranian drone into the Israeli airspace.

More news for Cymabay Therapeutics, Inc. Redmile Group LLC grew its holdings in shares of CymaBay Therapeutics by 21.6% in the fourth quarter. (NASDAQ:FLXN) for 31,423 shares. Tpg Group (Sbs) Advisors Inc accumulated 936,507 shares or 0.37% of the stock. The New York-based Metropolitan Life Insurance Ny has invested 0% in Flexion Therapeutics, Inc. Moreover, Rbf Capital has 0.4% invested in Entegris, Inc. According to the Analysts, the Low Earnings estimate for the current quarter is $-0.23, while the High earnings estimate is $-0.05.Comparatively, EPS for the same quarter previous year was $-0.32. D E Shaw And Company Incorporated has invested 0% in Flexion Therapeutics, Inc. The stock is noticeable among investors as ILMN reported favorable performance of 2.11%. 29,023 are owned by Savings Bank Of America De. Eaton Vance Mgmt stated it has 0% in Flexion Therapeutics, Inc.

CymaBay Therapeutics Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to treat specialty and orphan diseases. The stock has a market capitalization of $668.41 Million however its outstanding shares are 44.95 Million. It lead product candidate includes Zilretta, a late-stage, intra-articular, extended-release investigational steroid treatment that has completed Phase 3 clinical trials for IA therapy for patients with moderate and severe osteoarthritis pain. The simple logic that a stock's current market price does not justify (is not equivalent to) its higher earnings and therefore has room to run is behind shareholders' inclination toward low P/E stocks. Its up 0.65, from 0.6 in 2017Q2. Institutional investors own 60.30% stake in the company while Beta factor, which is used to measure riskiness of the security, was 1.87. 38 funds opened positions while 59 raised stakes. Of those transactions, there were 178,846 shares of CBAY bought and 1.2 million shares sold. (NASDAQ:FLXN). Citadel Limited Liability has invested 0% in Flexion Therapeutics, Inc. Gilder Gagnon Howe Com Ltd Com holds 3.96 million shares. Laurion Management Ltd Partnership reported 5,200 shares stake. Schroder Mngmt Grp holds 0.49% or 7.46 million shares. Janney Montgomery Scott Ltd Liability Corp invested in 0.01% or 19,045 shares. Gam Ag holds 0.13% or 130,500 shares in its portfolio. Trb Advisors Lp owns 477,500 shares or 37.21% of their United States portfolio. The shares were sold at an average price of $15.89, for a total transaction of $3,464,925.73. Mirae Asset Global Invs holds 0.08% or 171,338 shares. Provident Trust Co, a Wisconsin-based fund reported 2.59 million shares.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.